January is Love Your Liver Awareness Month.
In recognition, we present seven of the most important liver studies published in BJS and BJS Open over the past year. These articles highlight significant advancements in the understanding and management of liver-related conditions, particularly hepatocellular carcinoma (HCC). Covering topics such as innovative surgical techniques, comparative treatment outcomes, and prognostic markers, this collection showcases the latest research aimed at improving care and outcomes for patients with liver diseases.
Dive into these key contributions to the field and join us in raising awareness of liver health this January.
______
BJS highlights:
______
Laparoscopic right anterior inferior segmentectomy for hepatocellular carcinoma in a patient with congenital absence of the portal vein: intrahepatic artery-guided simulation.
This report discusses congenital absence of the portal vein (CAPV), a rare condition occurring in approximately 1 in 30,000 individuals, and its association with hepatic tumors such as hepatocellular carcinoma. CAPV poses challenges for anatomical liver resection due to the lack of an intrahepatic portal vein, a key surgical landmark. The intrahepatic artery is proposed as an alternative guide for resection in these patients, offering a feasible approach to managing CAPV-related tumors. Read the paper.
______
Laparoscopic liver resection versus radiofrequency ablation for small hepatocellular carcinoma: randomized clinical trial.
This single-centre randomised controlled trial compared laparoscopic liver resection (LLR) and radiofrequency ablation (RFA) in patients with small hepatocellular carcinoma (HCC). The study found no significant differences in overall survival or recurrence-free survival between the two treatment groups over five years. However, LLR was associated with a higher complication rate and longer hospital stays, while RFA had a shorter procedure time and less invasiveness. These findings suggest that both treatments are viable, with the choice potentially guided by patient preferences, tumour characteristics, and resource availability. Read the paper.
______
Long-term outcomes of ruptured hepatocellular carcinoma: international multicentre study.
This multicentre retrospective study compared outcomes of ruptured and non-ruptured hepatocellular carcinoma (HCC) in 2033 patients, using propensity score matching. Patients with ruptured HCC exhibited significantly worse overall survival (median: 21 vs 54 months) and disease-free survival (median: 10 vs 22 months). Preoperative embolization and complete resection were identified as independent factors associated with improved survival in ruptured cases. These findings underscore the importance of optimizing preoperative strategies, such as embolization, to enhance outcomes for patients with ruptured HCC. Read the paper.
______
Liver transplantation for advanced hepatocellular carcinoma after downstaging with consequential lenvatinib, transcatheter arterial chemoembolization and camrelizumab.
This study analysed the outcomes of three patients with advanced hepatocellular carcinoma (HCC) and portal vein tumour thrombus who underwent liver transplantation (LT) after successful downstaging using lenvatinib, transcatheter arterial chemoembolization (TACE), and PD-1 inhibitors (LEN-TAP). All patients achieved complete tumour necrosis and remained recurrence-free with stable graft function at one-year post-transplant. The findings highlight the potential of LT as a curative option for select patients with advanced HCC who are ineligible for resection following effective downstaging, warranting further prospective investigation. Read the paper.
______
BJS Open highlights:
______
Liver resection versus radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis
This meta-analysis assessed outcomes of liver resection (LR), radiofrequency ablation (RFA), and trans-arterial chemoembolization (TACE) in patients with early-stage, oligo-nodular hepatocellular carcinoma (HCC). LR demonstrated superior 3- and 5-year overall survival compared to TACE and better disease-free survival compared to RFA, supporting its inclusion as a preferred treatment within the therapeutic hierarchy. These findings challenge current guidelines and highlight the need for further comparative cohort studies. Read the paper.
______
Prognostic value of aspartate aminotransferase/alanine aminotransferase ratio in hepatocellular carcinoma after hepatectomy
This retrospective study identified an AST/ALT ratio ≥1.4 as a significant prognostic marker for reduced overall and recurrence-free survival in patients undergoing hepatectomy for HCC. Chronic hepatitis B mediated a substantial proportion of this association, emphasizing the need to integrate liver disease management into oncological care. This study provides a potential biomarker for risk stratification and tailored follow-up. Read the paper.
______
Referral rate of patients with incidental gallbladder cancer and survival: outcomes of a multicentre retrospective study
A multicenter study of incidental gallbladder cancer patients revealed that referral to tertiary centers was suboptimal, with only 53.9% of eligible patients referred despite an indication for re-resection. Patients who were referred had significantly longer survival compared to those managed exclusively in secondary centers. These findings underscore the critical need for systematic referral practices to optimize outcomes for this rare but aggressive cancer. Read the paper.



